Caplacizumab (Cablivi)
Revision as of 00:37, 7 December 2018 by Warner-admin (talk | contribs) (Text replacement - "http://www.nejm.org" to "https://www.nejm.org")
Mechanism of action
A single domain antibody directed against the A1 domain of von Willebrand factor (vWF).
Preliminary data
Thrombotic thrombocytopenic purpura
- Peyvandi F, Scully M, Kremer Hovinga JA, Cataland S, Knöbl P, Wu H, Artoni A, Westwood JP, Mansouri Taleghani M, Jilma B, Callewaert F, Ulrichts H, Duby C, Tersago D; TITAN Investigators. Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2016 Feb 11;374(6):511-522. link to original article PubMed